A notable advancement in glucose management is emerging with the approval of tirzepatide at a dosage of 45mg. This new version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and offers a https://onelifesocial.com/story6755782/significant-introduction-tirzepatide-dose-for-glucose-control